Founded in Dec 31st 1998, Zhejiang Jianfeng Pharmaceutical Co., Ltd (Jianfeng Pharm) is a wholly-owned subsidiary of Zhejiang Jianfeng Group Co., Ltd (stock listed No.: 600668). Jianfeng Pharm has 5 drug production enterprises (by wholly-owned, holding and shareholding), 3 pharmaceutical handling enterprises, 3 national postdoctoral-centres, 2 provincial academician-workstations, 52 international
/ domestic pharmaceutical invention patents, and the market share of our leading products ranks among the top 3 in the domestic market. Jianfeng Pharm focuses on FDFs, chemical APIs / intermediates, natural plant extracts and herbals. In 2022, Jianfeng Pharm (FDF mainly) achieved revenue of 473 million CHY with tax 29.38 million CHY. The whole pharm area (including intermediates and herbal naturals) achieved revenue of 1.525 billion CHY with tax 103 million CHY. With investment of 532 million CHY, Jianfeng’s Pharm production base (Jinxi, section A + section B) takes up 130,000m2 area, uses the latest-tech & equipment to form the cephalosporin API workshop, common API workshop, anti-tumor API workshop, oral solid forms workshop and powder for injection workshop. The section A offers production capacity of 35 tons of API, 140 million vials of powder for injection, 500 million tablets, 70 million capsules and 800 million dripping pills. In Jul 2023, the section B passed US FDA inspection and offers production capacity of 2 billion tabs / caps (could be upgraded to 4 billion tabs / caps when needed). Our Gingko extracts & silybum marianum extracts granted with Korean KFDA, ginseng extracts granted with US FDA, Jianfeng new oral solid workshops granted with US FDA. Cefmenoxime hydrochloride for injection, paroxetine hydrochloride tablets, amlodipine aspartate tablets rise as Jianfeng’s key products with over-10 million CHY profit.
